ELDN
Eledon·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ELDN
Eledon Pharmaceuticals, Inc.
A clinical stage biotech company that develops treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS
19900 MacArthur Boulevard, Suite 550, Irvine, California 92612
--
Eledon Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on March 26, 2004. The company is a clinical-stage biopharmaceutical company focused on developing life-changing targeted drugs for people who require organ or cell-based transplantation, have autoimmune diseases, or have amyotrophic lateral sclerosis. The company's lead compound under development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target that they believe has broad therapeutic potential.
Company Financials
EPS
ELDN has released its 2025 Q3 earnings. EPS was reported at -0.21, versus the expected -0.25, beating expectations. The chart below visualizes how ELDN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
